Inhibiting calcium-activated chloride channels (CaCCs) can diminish the tumorigenic characteristics of ANO1, indicating that TMEM16A and its related channels are promising targets for the treatment of prostate cancer and other malignancies. Here, ANO1 is linked to prostate cancer.